8-K: Oscar Health Announces Executive Role Change

Oscar Health, Inc. has amended the employment agreement for Mario Schlosser, transitioning him from President of Technology and CTO to Co-Founder & Advisor to the CEO, effective June 1, 2026.

Summary

• Mario Schlosser is transitioning from his role as President of Technology and Chief Technology Officer at Oscar Health, Inc. to a new position as Co-Founder & Advisor to the CEO.
• This change is effective June 1, 2026, and is formalized through an amended and restated employment agreement.
• In his new capacity, Mr. Schlosser will focus on advancing the company's artificial intelligence and digital health initiatives.
• He will continue to serve on the company's Board of Directors.
• His annual base salary will be $370,000.
• Mr. Schlosser will no longer be eligible for annual bonuses starting in calendar year 2026.
• He will not receive new long-term incentive or equity awards but will continue to vest in previously granted equity.
• No cash severance or company-subsidized healthcare will be provided upon termination of employment.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it signifies a continued strategic focus on innovation areas like AI and digital health, though the executive's compensation structure has been adjusted.

Positives

• Continued focus on AI and digital health innovation through Mr. Schlosser's new advisory role.
• Mr. Schlosser retains his position on the Board of Directors, ensuring continued strategic input.
• Mr. Schlosser will continue to vest in previously granted equity awards.

Negatives

• Mr. Schlosser is no longer eligible for annual bonuses starting in calendar year 2026.
• Mr. Schlosser will not be eligible for any new long-term incentive or equity-based compensatory awards.
• Mr. Schlosser will not receive any cash severance payments or company-subsidized healthcare coverage upon termination.

Risks

• Potential impact on technological innovation if Mr. Schlosser's advisory role is not effectively integrated.
• Risk of reduced employee morale if the transition is perceived negatively by other key personnel.
• Uncertainty regarding the long-term impact of reduced incentive structures on executive retention and motivation.

Future Outlook

The filing does not contain specific forward-looking financial guidance. However, it indicates a continued strategic focus on accelerating artificial intelligence and digital health initiatives.

Management Comments

• Mr. Schlosser will continue accelerating the Company's artificial intelligence and digital health agenda to drive the next wave of innovation in consumer-driven healthcare across the U.S.

Industry Context

StockSavvy.ai notes that this executive transition at Oscar Health, Inc. reflects a broader industry trend of healthcare companies prioritizing AI and digital health to enhance consumer experience and operational efficiency. The shift in Mr. Schlosser's role suggests a strategic deepening of focus in these critical areas.

Management Changes

Stakeholder Impact

• Shareholders: Potential positive impact if AI and digital health initiatives lead to improved company performance. Neutral impact from the executive compensation adjustments.
• Employees: May be influenced by the continued focus on innovation, but potential concerns regarding executive compensation changes.
• Management: Adjustment in compensation structure for a key executive.

Next Steps

• Mr. Schlosser to assume new role as Co-Founder & Advisor to the CEO, focusing on AI and digital health.
• Continued vesting of Mr. Schlosser's previously granted equity awards.

Key Dates

Keywords

Oscar Health, Mario Schlosser, Executive Transition, Technology, Artificial Intelligence, Digital Health, Employment Agreement, Board of Directors